Gilead Sciences - GILD Stock Forecast, Price & News

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GILD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View GILD analyst ratings or view top-rated stocks.

17 Wall Street research analysts have issued 1 year price targets for Gilead Sciences' stock. Their GILD share price forecasts range from $70.00 to $112.00. On average, they anticipate the company's share price to reach $89.40 in the next year. This suggests a possible upside of 14.2% from the stock's current price.
View analysts price targets for GILD or view top-rated stocks among Wall Street analysts.

Gilead Sciences' stock was trading at $85.85 at the beginning of the year. Since then, GILD shares have decreased by 8.9% and is now trading at $78.25.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our GILD earnings forecast.

Gilead Sciences, Inc. (NASDAQ:GILD) released its earnings results on Thursday, February, 2nd. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.17. The biopharmaceutical company had revenue of $7.39 billion for the quarter, compared to the consensus estimate of $6.63 billion. Gilead Sciences had a trailing twelve-month return on equity of 44.46% and a net margin of 16.83%. The company's revenue was up 2.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.69 earnings per share.
Read the conference call transcript.

Gilead Sciences announced a quarterly dividend on Thursday, February 2nd. Investors of record on Wednesday, March 15th will be paid a dividend of $0.75 per share on Thursday, March 30th. This represents a $3.00 dividend on an annualized basis and a yield of 3.83%. The ex-dividend date of this dividend is Tuesday, March 14th. This is a positive change from the stock's previous quarterly dividend of $0.73.
Read our dividend analysis for GILD.

ETFs with the largest weight of Gilead Sciences (NASDAQ:GILD) stock in their portfolio include VanEck Biotech ETF (BBH), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust Nasdaq Pharmaceuticals ETF (FTXH), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Dynamic Pharmaceuticals ETF (PJP), Invesco Dynamic Biotechnology & Genome ETF (PBE) and ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA).

Gilead Sciences (NASDAQ:GILD) pays an annual dividend of $3.00 per share and currently has a dividend yield of 3.88%. The company has been increasing its dividend for 8 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 82.19%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, GILD will have a dividend payout ratio of 40.87% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GILD.

Gilead Sciences issued an update on its FY 2023 earnings guidance on Thursday, February, 2nd. The company provided earnings per share (EPS) guidance of $6.60-$7.00 for the period, compared to the consensus EPS estimate of $6.73. The company issued revenue guidance of $26.00 billion-$26.50 billion, compared to the consensus revenue estimate of $25.76 billion.

107 employees have rated Gilead Sciences Chief Executive Officer Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among the company's employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (1.90%), Morgan Stanley (1.37%), Norges Bank (1.04%), Parnassus Investments LLC (0.96%), Legal & General Group Plc (0.85%) and Amundi (0.81%). Insiders that own company stock include Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Javier Rodriguez, Johanna Mercier, John Francis Cogan, Merdad Parsey and Richard James Whitley.
View institutional ownership trends.

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GILD stock can currently be purchased for approximately $78.25.

Gilead Sciences (NASDAQ:GILD) has a market capitalization of $97.59 billion and generates $27.28 billion in revenue each year. The biopharmaceutical company earns $4.59 billion in net income (profit) each year or $3.65 on an earnings per share basis.

The company employs 17,000 workers across the globe.

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The official website for the company is www.gilead.com. The biopharmaceutical company can be reached via phone at (650) 574-3000, via email at investor_relations@gilead.com, or via fax at 650-578-9264.